What the research found

When people lose weight through diet alone, their bodies mount a coordinated counter-attack: hunger-driving hormones like ghrelin rise, while satiety signals (PYY, CCK, natural GLP-1) fall. Simultaneously, energy expenditure drops by 150–250 calories daily beyond what their smaller body size would predict—a process called adaptive thermogenesis. A 2025 analysis across 127 studies confirms this pattern scales with loss magnitude, and a 2011 trial showed these shifts persist more than a year later, even after some weight regain.

GLP-1 receptor agonists like semaglutide appear to interrupt part of this adaptation. Analysis of blood from major trials (STEP 1, STEP 2) found semaglutide prevented the typical drop in PYY and amylin, and actually increased CCK—suggesting it blunts the hormonal "rebound" that normally drives regain. Tirzepatide (a dual GIP/GLP-1 agonist) boosts fat burning and reduces intake but does not override the adaptive thermogenesis signal.

Both drugs eventually plateau: semaglutide 2.4 mg stabilises around week 60 and holds through 2–4 years of follow-up; tirzepatide 5 mg plateaus similarly, while higher tirzepatide doses (10–15 mg) showed ongoing loss through trial end. The plateau likely reflects the body reaching a new equilibrium, not receptor "burnout"—the mechanism at the receptor level appears intact.

Why it matters for you

If you've hit a plateau on your current dose, the mechanism isn't that the drug has stopped working at the cellular level. Your body has adjusted to the new dose, much as it adjusts to a lower weight. Increasing dose often restarts loss because you're shifting the hormonal balance further in favour of reduced appetite and intake—it's a titration problem, not a failure of the drug itself.

For biomarker tracking, this explains why hunger and energy expenditure are moving targets during weight loss, even on medication. Your fasting ghrelin may creep up, leptin may drop further, and your basal metabolic rate may fall despite no change in muscle mass or activity. These aren't signs the protocol is broken; they're signals your system is defending. If you're also tracking body composition, expect that the later phases of loss (after the initial rapid drop) become slower and more metabolically "expensive" to achieve.

This also has practical implications for dosing decisions. If you're on a stable dose and hunger has returned, increasing is pharmacologically justified—you're not fooling your body into complacency, you're maintaining the hormonal advantage the drug provided at a lower dose. Conversely, if you're stable and satisfied at your current dose, there's no biochemical mandate to escalate.

Caveats

• Observational and trial-derived: The hormonal data come from existing trial blood samples, not purpose-designed mechanistic studies; causation is inferred, not proven.
• Species and context variation: Adaptive thermogenesis magnitude varies by individual; the 150–250 calorie range is a population average.
• Long-term brain effects unknown: While receptor function appears preserved, central nervous system adaptation (how the brain interprets these signals over years) is not well characterised.
• Limited tirzepatide data on adaptation: Fewer mechanistic studies exist for tirzepatide versus semaglutide.
• Plateau definition varies: "Plateau" in trials is a statistical threshold, not zero weight change; slow ongoing loss may continue unnoticed.